Chester County News and Community Website
ATLANTA, GA — The Centers for Disease Control and Prevention on Tuesday adopted a major change to its childhood immunization guidance, giving parents greater discretion over whether and when their …
CDC Shifts Course on Hepatitis B Birth Shot, Giving Parents New Say Read More
ATLANTA, GA — Federal health officials made two consequential moves this month affecting infant health, as advisers voted to loosen long-standing guidance on newborn hepatitis B vaccination while investigators expanded …
CDC Shifts Hep B Guidance as Infant Formula Outbreak Sickens 51 Babies Read More
HARRISBURG, PA — The Pennsylvania Department of Health on Thursday detailed a series of major investments and policy actions aimed at strengthening emergency medical services, expanding access to period products …
New Funding, Free Supplies, and Firm Vaccine Guidance Mark Big Week for PA Health Policy Read More
ATLANTA, GA — A key federal advisory panel voted Friday to endorse a more flexible, parent-driven approach to infant hepatitis B vaccination, marking a significant departure from longstanding U.S. policy …
CDC Panel’s Hepatitis B Shift Sparks New Debate Over Infant Vaccinations Read More
PHILADELPHIA, PA — Virion Therapeutics, LLC announced that new clinical data from its VRON-0200 program for chronic Hepatitis B virus (HBV) infection will be featured in an oral presentation at …
Virion Therapeutics to Present New Chronic Hepatitis B Data at AASLD Liver Meeting Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, imdusiran and AB-101, at the European Association for the Study of the …
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for presentation at the European Association for the Study of the Liver …
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced promising new data from its IM-PROVE I Phase 2a clinical trial, suggesting significant advancements in treatment for chronic hepatitis B …
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment Read More WARMINSTER, PA and OXFORD, United Kingdom — Arbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their Phase 2a IM-PROVE II clinical trial at the American Association …
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released new data from their Phase 2a clinical trial, IM-PROVE I, revealing that imdusiran, their RNAi therapeutic, in combination with a …
Advancing Towards a Functional Cure: Promising Results in Hepatitis B Treatment Read More